Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03952806 · ClinicalTrials.gov registry record · Phase 3
Study of BHV-3241 in Participants With Multiple System Atrophy
A Phase 3 study, sponsored by Biohaven Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 421
- Enrollment target
NCT03952806 is a Phase 3 study that has completed, run by Biohaven Pharmaceuticals. The registered enrollment target is 421 participants.
The verdict
NCT03952806, a Phase 3 study, has completed, sponsored by Biohaven Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 421 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy of verdiperstat (BHV-3241) versus placebo in participants with Multiple System Atrophy
Interventions
- DRUG Placebo
- DRUG Verdiperstat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 421 participants |
| Start Date | 2019-07-29 |
| Est. Completion | 2022-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03952806
The ClinicalTrials.gov registry entry for NCT03952806 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 421 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biohaven Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03952806 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03952806 about?
NCT03952806 is a clinical study titled "Study of BHV-3241 in Participants With Multiple System Atrophy". The purpose of this study is to compare the efficacy of verdiperstat (BHV-3241) versus placebo in participants with Multiple System Atrophy
What is the current status of trial NCT03952806?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 421 participants. The study started on 2019-07-29. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT03952806?
The interventions under investigation include: Placebo (DRUG), Verdiperstat (DRUG).
Who is sponsoring clinical trial NCT03952806?
This trial is sponsored by Biohaven Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.